Moderna Inc. ($MRNA) Stock Forecast: Down 8.4% Today

What is Moderna Inc.?

Moderna (NASDAQ: MRNA) is a biotechnology company known for its development of mRNA-based vaccines, including the widely used COVID-19 vaccine. Today, the stock experienced a strong bearish movement in the market.

Why is Moderna Inc. going down?

MRNA stock is down 8.4% on Jan 28, 2026 14:45

• An analyst initiated coverage on Moderna with an "equal weight" rating and a $25.00 price target, indicating a significant downside potential from its current price. This negative sentiment from analysts likely contributed to the bearish movement.
• The weak fundamentals of Moderna, such as negative EPS and revenue declines, could have further fueled investor concerns and led to the sell-off.
• The lack of growth in revenue and poor financial outlook for biotech companies like BioNTech SE, may have cast a shadow on Moderna's prospects, impacting its stock performance.
• Overall, the combination of negative analyst ratings, weak financial fundamentals, and broader industry concerns about revenue growth in the biotech sector likely contributed to Moderna's bearish market movement today.

MRNA Price Chart

MRNA Technical Analysis

MRNA News

Moderna (NASDAQ:MRNA) Coverage Initiated at Barclays

Barclays has initiated coverage on Moderna (NASDAQ:MRNA) with an "equal weight" rating and a $25.00 price target, suggesting a significant downside from its current price. This rating aligns with a broader analyst consensus of "Reduce" for the stock, with 12 Holds and 5 Sells against 2 Buys. The report highlights weak fundamentals for Moderna, including negative EPS and revenue declines, and forecast an EPS of -9.61 for the current year.

https://www.marketbeat.com/instant-alerts/moderna-nasdaqmrna-coverage-initiated-at-barclays-2026-01-28/

BioNTech SE's (NASDAQ:BNTX) Price Is Right But Growth Is Lacking After Shares Rocket 26%

BioNTech's share price saw a 26% gain in the last month, but is still down 4% over the past year. Despite its current price-to-sales ratio suggesting a potential buying opportunity compared to the industry average, the company's revenue growth has been poor, with analysts forecasting a continued decline. This lack of growth justifies its low P/S ratio, indicating that a significant stock price increase is unlikely without a material change in its financial outlook.

https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-bntx/biontech/news/biontech-ses-nasdaqbntx-price-is-right-but-growth-is-lacking

RNA-Targeted Small Molecule Drugs Market Is Going to Boom |•

The report "RNA-Targeted Small Molecule Drugs Market" provides a comprehensive analysis of the global market from 2026 to 2033. It includes insights into market growth, consumption, size, revenue, share, trends, and cost structures, covering key players like Ionis Pharmaceuticals, Moderna, and Alnylam Pharmaceuticals. The study segments the market by type (Oncology, Infectious Diseases, etc.) and applications (Cancer therapy, Viral infection treatment, etc.), addressing market drivers, challenges, and opportunities across various geographic regions.

https://www.openpr.com/news/4366702/rna-targeted-small-molecule-drugs-market-is-going-to-boom

Lexeo Therapeutics appoints new COO and CMO, announces executive transition

Lexeo Therapeutics has announced significant executive leadership changes, appointing Jose Manuel Otero, Ph.D., as Chief Operating Officer and Narinder P. Bhalla, M.D., as Chief Medical Officer. Dr. Bhalla succeeds Eric Adler, M.D., who will transition to President and CEO of Myoventive, Inc. These announcements follow recent interim Phase I/II data for their gene therapy LX2020, with varying analyst reactions to the clinical findings.

https://ng.investing.com/news/sec-filings/lexeo-therapeutics-appoints-new-coo-and-cmo-announces-executive-transition-93CH-2307247

Japanese trade program selects Ernexa Therapeutics among elite biotech group

Ernexa Therapeutics, a microcap biotech company developing cell therapies for cancer and autoimmune diseases, has been selected to participate in the Japan Entry Acceleration Program (JEAP). This program, launched by JETRO, aims to support foreign regenerative medicine companies entering the Japanese market. Ernexa will receive mentoring and guidance on regulatory and commercial landscapes in Japan, and explore collaborations, despite its current financial challenges.

https://ca.investing.com/news/company-news/japanese-trade-program-selects-ernexa-therapeutics-among-elite-biotech-group-93CH-4420858

Trending Today

Worldcoin ($WLD) Crypto Forecast: Up 14.0% Today

Gold ($XAU) Commodity Forecast: Up 6.4% Today

Albemarle Corporation ($ALB) Stock Forecast: Down 5.1% Today

Microchip Technology Incorporated ($MCHP) Stock Forecast: Up 6.3% Today

Corning Incorporated ($GLW) Stock Forecast: Down 5.2% Today

Texas Instruments Incorporated ($TXN) Stock Forecast: Up 9.5% Today

Sunrun Inc. ($RUN) Stock Forecast: Up 5.1% Today

Elevance Health Inc. ($ELV) Stock Forecast: Up 5.4% Today

Western Digital Corporation ($WDC) Stock Forecast: Up 11.3% Today

Lemonda Inc. ($LMND) Stock Forecast: Up 5.5% Today

Moderna Inc. Price History

27.00.2026 - MRNA Stock was up 6.0%

• MRNA stock experienced a bullish movement today.
• The positive market sentiment towards MRNA could be attributed to recent advancements in personalized cancer vaccines by another company, potentially boosting confidence in the biotech sector.
• Additionally, positive developments in the biotech industry, such as progress with a therapy for bladder cancer by another company, may have created a ripple effect of optimism among investors, benefiting companies like MRNA.
• Overall, the growing interest and potential breakthroughs in the biotech field seem to have contributed to the bullish movement in MRNA stock today.

27.00.2026 - MRNA Stock was down 5.2%

• Moderna (MRNA) underwent a period of bearish movement, potentially influenced by positive developments and growth projections of major competitors in the oncology market, including Merck (MRK), Oncolytics Biotech Inc. (ONCY), and other industry participants.
• Merck's (MRK) anticipated rise in earnings and revenues, progress in its oncology pipeline, and revised growth forecasts might have redirected investor attention from Moderna, leading to a decline in its stock performance.
• Analysts' call for enhanced clarity on long-term growth prospects at Merck, despite its notable performance, may have prompted investor apprehensions regarding Moderna's competitiveness and future growth trajectory in biotechnology.
• References to AI stocks presenting superior upside potential compared to Merck could have shifted investor focus towards alternative investment options, thereby contributing to the downward trend in Moderna's stock value.

23.00.2026 - MRNA Stock was down 10.9%

• The stock's decline may have been driven by profit-taking by investors following a recent 4% rally linked to positive five-year follow-up data for their mRNA cancer vaccine in collaboration with Merck.
• Concerns about potential competition or market positioning for Moderna in the oncology sector could have arisen with the amendment of the license agreement between Terns Pharmaceuticals and Hansoh for TERN-701 rights.
• Investor focus and capital might have been redirected towards the banking sector, particularly awaiting Itaú Unibanco's Q4 results, contributing to Moderna's downward trend.
• Despite the promising long-term prospects in oncology, external factors and short-term market dynamics possibly influenced the bearish performance today.

23.00.2026 - MRNA Stock was down 9.4%

• Moderna's stock saw a strong bearish movement possibly due to the announcement of limiting investment in new late-stage vaccine trials, reflecting concerns over achieving returns amidst regulatory hurdles and opposition in the US market.
• The groundbreaking five-year follow-up data for their mRNA cancer vaccine, which demonstrated positive results in high-risk melanoma patients, might have been overshadowed by the decision to curb vaccine trial investments, leading to investor uncertainty.
• The amended license agreement with Hansoh for TERN-701 by Terns Pharmaceuticals could have also impacted Moderna's stock negatively, as it potentially shifts focus and resources away from certain therapeutic products.
• Overall, the market may be reacting to the shifting priorities and strategies within Moderna, as it navigates challenges in the regulatory landscape and transitions towards personalized cancer treatments, impacting investor sentiment and stock performance.

23.00.2026 - MRNA Stock was down 10.7%

• The stock's decline could be attributed to profit-taking or concerns about vaccine distribution challenges.
• Positive updates on Lucid Group, Materion Corp, and Terns Pharmaceuticals might have shifted investor focus away from Moderna.
• Other companies' positive news and Itaú Unibanco's upcoming investor meeting could have added to the downward pressure on Moderna's stock.
• Despite today's bearish movement, Moderna's long-term outlook remains optimistic due to its crucial role in the pandemic response and continuous vaccine innovations.

28.00.2026 - MRNA Stock was down 8.4%

• An analyst initiated coverage on Moderna with an "equal weight" rating and a $25.00 price target, indicating a significant downside potential from its current price. This negative sentiment from analysts likely contributed to the bearish movement.
• The weak fundamentals of Moderna, such as negative EPS and revenue declines, could have further fueled investor concerns and led to the sell-off.
• The lack of growth in revenue and poor financial outlook for biotech companies like BioNTech SE, may have cast a shadow on Moderna's prospects, impacting its stock performance.
• Overall, the combination of negative analyst ratings, weak financial fundamentals, and broader industry concerns about revenue growth in the biotech sector likely contributed to Moderna's bearish market movement today.

21.00.2026 - MRNA Stock was up 16.9%

• Moderna's bullish movement today could be attributed to the broader positive sentiment in the cell and gene therapy market, driven by technological advancements and increasing demand for personalized medicine.
• Analysts' bullish outlook on Merck & Co. (MRK) and its potential acquisition of Revolution Medicines to strengthen its oncology pipeline may have positively influenced investor confidence in the biotech sector, including Moderna.
• The significant vaccine delivery licensing deal involving Pfizer and Novavax might have also boosted investor optimism in the biopharmaceutical industry, reflecting positively on Moderna's innovative approaches in vaccine development.
• Overall, the positive market movements in the biotech and pharmaceutical sectors, coupled with strategic advancements and collaborations within the industry, likely contributed to Moderna's strong bullish performance today.

21.00.2026 - MRNA Stock was up 11.6%

• The bullish movement in Moderna's stock today is influenced by the positive reception of the five-year follow-up data from its Phase IIb trial for a personalized mRNA-based cancer therapy, showing promising results for high-risk melanoma patients.
• Analyst sentiment toward Moderna remains optimistic, with BofA Securities recently raising its price target. Despite concerns about the stock valuation exceeding target levels and potential challenges in the oncology market, long-term confidence driven by strategic shifts and partnerships is boosting investor morale.
• Market movements within the biotechnology sector, such as news of acquisitions and licensing agreements by competitors like Merck and Novavax, may have also contributed to Moderna's positive momentum as investors recognize growth opportunities in the industry.
• Moderna's strategic focus on oncology, along with progress in its pipeline and favorable analyst outlook, positions the company well for future growth and innovation in the healthcare sector.

22.00.2026 - MRNA Stock was up 15.0%

• Moderna's bullish movement could be attributed to positive sentiment surrounding the company's COVID-19 vaccine sales and ongoing efforts in vaccine development.
• The market may be reacting favorably to the news of a global restructuring, potentially indicating investor confidence in companies adapting to optimize operations.
• Steady stock performance and positive outlook from an analyst firm could be contributing to a positive overall sentiment in the healthcare sector, benefiting companies like Moderna.
• A stock hitting a 52-week high and the positive analyst price target revisions could be boosting investor interest in the biotech sector, indirectly benefiting Moderna as well.

22.00.2026 - MRNA Stock was up 10.6%

• Moderna's bullish movement today could be attributed to positive sentiment surrounding the broader biotech sector and the company's ongoing efforts in vaccine development.
• The bullish market movement may also be influenced by the news of Bristol Myers partnering with Janux Therapeutics to develop novel tumor-activated therapeutics, highlighting the potential for innovative approaches in the healthcare industry.
• Additionally, the strong performance of other healthcare companies like Liquidia Technologies hitting an all-time high could have created a positive ripple effect in the sector, boosting investor confidence in Moderna's growth prospects.
• Overall, Moderna's bullish trend today seems to be driven by a combination of sector-wide optimism, positive developments in the healthcare industry, and potentially favorable market conditions for biotech companies.

22.00.2026 - MRNA Stock was up 12.0%

• The positive sentiment surrounding the efficacy and demand for Moderna's COVID-19 vaccine, as well as advancements in its pipeline for mRNA-based therapies, likely fueled the recent bullish movement.
• The collaboration between Janux Therapeutics and Bristol Myers Squibb could have played a role in boosting investor interest in biotech companies like Moderna.
• Abbott Laboratories' stock decline following revenue estimates miss may have indirectly benefited Moderna as investors potentially sought out companies with stronger growth potential.
• The selling of Merck & Co., Inc. shares by Bailard Inc. and other hedge funds may have shifted investments towards promising opportunities like Moderna, contributing to its bullish performance.

22.00.2026 - MRNA Stock was up 8.2%

• Moderna's stock surged by 4% following the groundbreaking five-year follow-up data for their mRNA cancer vaccine, showing a significant reduction in the risk of relapse or death in high-risk melanoma patients. This success not only boosted investor confidence in Moderna's technology but also solidified its position as a major player in oncology.
• The announcement of Moderna curbing investments in vaccine trials due to US backlash had a positive impact on the stock, with shares jumping by 10.16% in morning trading. This strategic shift towards personalized cancer treatments in response to regulatory hurdles demonstrates the company's adaptability and focus on long-term growth.
• The partnership between Bristol Myers Squibb and Janux Therapeutics in developing novel T cell engagers for solid tumors may have indirectly contributed to Moderna's bullish movement by highlighting the potential in oncology treatments, further fueling optimism in the biotech sector.
• Overall, Moderna's bullish market movement today can be attributed to its groundbreaking cancer vaccine data, strategic shift towards personalized treatments, and positive investor sentiment towards advancements in oncology therapies.